One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Record caution: Label-version change: the May 2026 DailyMed pediatric renal table is now local. Older pediatric evidence-gap statements remain historical; read the new age-specific source before selecting a regimen.
U.S. labeling, UCSF and Nebraska distinguish indication and infusion duration. Nebraska uses a 4-hour inpatient infusion; the label uses 1 hour. Keep each renal table with its indication and infusion method.
The RX label table uses a one-hour infusion. The UCSF protocol uses a three-hour infusion. Both also separate urinary/intra-abdominal infection from pneumonia/severe infection.
What to reconcile: Keep the selected source dose, indication, renal band, loading instruction and infusion duration together.
Open this note and its source referencesThe older mirror lacks the age-specific renal regimens now supplied by the May 2026 label.
What to reconcile: Use the new pediatric card for ages two and older; verify indication, pediatric eGFR, weight caps and infusion time. Do not use adult Cockcroft-Gault bands as pediatric instructions.
Open this note and its source referencesLoading and maintenance infusions all last 3 hours. This is the institutional prolonged-infusion strategy, not a silent replacement for labeling. No non-dialysis dose below the printed range is inferred.
| CrCl, mL/min | Source-specific dose / instruction |
|---|---|
| >50 | 1.5 g every 8 hours |
| 30-50 | 750 mg every 8 hours |
| 15-29 | 375 mg every 8 hours |
| CrCl, mL/min | Source-specific dose / instruction |
|---|---|
| >50 | 3 g every 8 hours |
| 30-50 | 1.5 g every 8 hours |
| 15-29 | 750 mg every 8 hours |
| Dialysis setting / indication | Source-specific schedule |
|---|---|
| IHD - complicated UTI | 750 mg loading, then 150 mg every 8 hours |
| IHD - pneumonia/severe infection | 2.25 g loading, then 450 mg every 8 hours |
| Continuous HD | No regimen provided in the selected source |
All listed infusions last 3 hours. For CrCl >50 / 30-50 / 15-29 mL/min:
IHD, complicated UTI: 750 mg loading, then 150 mg every 8 hours. IHD, pneumonia/severe infection: 2.25 g loading, then 450 mg every 8 hours. These loading and maintenance infusions also last 3 hours. The reviewed UCSF page provides no continuous-HD regimen. This institutional prolonged-infusion strategy is not silently substituted for the product label.
RDM30-007-ceftolozane-tazobactam-1 · Source locator: UCSF - ZERBAXA: urinary versus severe infection; renal/dosing sections and stated qualifiers
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=ceftolozane-tazobactam&s1=RDM30-007-ceftolozane-tazobactam&h1=efb9431568d6de612925b6f03d7f037778f5fedc6b6420adf3b7f6e27e394f87